BioAge Labs, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $9.0M | $0 | — | — |
| Research and development | $74.0M | $59.0M | $33.9M | — |
| Operating expenses | $101.8M | $78.2M | $48.4M | — |
| Operating income | -$92.8M | -$78.2M | -$48.4M | — |
| Interest expense | $697,000 | $2.4M | $7.8M | — |
| Pretax income | -$80.6M | -$71.1M | -$63.9M | — |
| Income tax expense | $0 | $0 | $0 | — |
| Net income | -$80.6M | -$71.1M | -$63.9M | — |
| Balance Sheet | ||||
| Cash and equivalents | $188.9M | $354.3M | $21.6M | — |
| Current assets | $286.8M | $357.1M | $25.3M | — |
| Total assets | $294.9M | $358.2M | $25.9M | — |
| Current liabilities | $20.1M | $27.8M | $58.2M | — |
| Total liabilities | $22.8M | $35.1M | $66.6M | — |
| Total debt | $2.0M | $8.0M | — | — |
| Stockholders' equity | $272.1M | $323.1M | -$173.4M | -$112.6M |
| Cash Flow Statement | ||||
| Cash from operations | -$81.6M | -$51.5M | -$37.4M | — |
| Depreciation and amortization | $200,000 | $200,000 | $200,000 | — |
| Stock-based compensation | $11.7M | $7.0M | $3.0M | — |
| Capital expenditure | $719,000 | $366,000 | $166,000 | — |
| Free cash flow | -$82.3M | -$51.9M | -$37.5M | — |
Shares outstanding 44.5M · Free float 77.7%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.